Shares of Sana Biotechnology (SANA), a clinical-stage biotechnology company, skyrocketed over 236% in premarket trading on Wednesday. This massive surge comes after the company announced positive results from a clinical trial for its experimental type 1 diabetes treatment using cell transplantation.
The treatment aims to help the body produce its own insulin by transplanting cells that can regulate blood sugar levels. According to the study led at Uppsala University Hospital, the results "provide real hope that a scalable, curative treatment for patients with Type 1 diabetes, meaning normal blood glucose with no insulin injections or immunosuppression, is possible."
Analysts have reacted enthusiastically to the news, with several firms upgrading their ratings and price targets on Sana Biotechnology's stock. The breakthrough data has fueled optimism about the potential of this novel diabetes treatment approach, causing investor excitement and the dramatic premarket rally in SANA shares.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。